March 3, 2026

NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a 46.68% Potential Upside Amidst Strong Buy Ratings

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a Netherlands-based biopharmaceutical firm, is currently capturing investor attention with its significant growth potential and a robust lineup of analyst endorsements. Operating within the..

CG Oncology, Inc. (CGON) Stock Analysis: A 39% Potential Upside in the Battle Against Bladder Cancer

CG Oncology, Inc. (NASDAQ: CGON) stands as a formidable player in the healthcare sector, specifically within the biotechnology industry. With a market capitalization of $4.77 billion, this Irvine, California-based company..

Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring the 316.79% Potential Upside

For investors seeking high-growth opportunities in the biotechnology sector, Janux Therapeutics, Inc. (NASDAQ: JANX) offers an intriguing proposition with its remarkable potential upside. As a clinical-stage biopharmaceutical company, Janux is..

Ascentage Pharma Group Internat (AAPG): Investor Outlook on a Biotech Innovator with 108% Upside Potential

Ascentage Pharma Group International (AAPG), a pioneering force in the biotechnology industry, is capturing investor attention with its ambitious pipeline of therapies poised to address critical healthcare needs, ranging from..

Scholar Rock Holding Corporation (SRRK) Stock Analysis: A Biotech Gem with 15.82% Upside Potential

Scholar Rock Holding Corporation (NASDAQ: SRRK), a budding entity in the biotechnology landscape, commands attention with its promising pipeline and a robust market cap of $4.44 billion. Headquartered in Cambridge,..

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring a 145% Upside Potential Amidst Strong Analyst Support

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is capturing investor attention with its ambitious pipeline and potential for significant upside. As a biotechnology company focused on rare and ultra-rare genetic diseases, Ultragenyx..

Beam Therapeutics Inc. (BEAM): Investor Outlook with 74% Potential Upside in the Biotech Sector

Beam Therapeutics Inc. (NASDAQ: BEAM) is making waves in the biotechnology sector with its precision genetic medicines, targeting serious diseases through innovative therapies. With a market capitalization of $2.91 billion,..

Brookdale Senior Living Inc. (BKD): Investor Outlook Highlights 28% Upside Potential

Brookdale Senior Living Inc. (BKD) is a pivotal player in the healthcare sector, specifically within the medical care facilities industry in the United States. With a market capitalization of $3.6..

Acadia Healthcare (ACHC) Stock Analysis: A Closer Look at its Challenges and Potential Amidst a -3.10% Upside

Investors interested in the healthcare sector, particularly the niche market of behavioral healthcare services, may find Acadia Healthcare Company, Inc. (NASDAQ: ACHC) a noteworthy candidate. With a market capitalization of..

Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring a 178% Upside Potential

Viking Therapeutics, Inc. (NASDAQ: VKTX) has emerged as a compelling player in the biotechnology sector, capturing the attention of investors with its innovative pipeline and substantial upside potential. With a..

PACS Group, Inc. (PACS) Stock Analysis: A Promising 20.63% Upside in the Healthcare Sector

PACS Group, Inc. (PACS), a prominent player in the healthcare sector, is capturing investor attention with its impressive potential upside of 20.63%. Specializing in the operation of skilled nursing and..

Alvotech (ALVO) Stock Analysis: Exploring a Potential 375% Upside in the Biosimilar Market

Alvotech (NASDAQ: ALVO), a Luxembourg-based company specializing in the development and manufacture of biosimilar medicines, has caught the attention of investors with its promising growth potential. Despite a current price..

Galapagos NV (GLPG): Unpacking the 1,093% Revenue Growth and What It Means for Investors

Investors with an eye on the biotechnology sector might find Galapagos NV (NASDAQ: GLPG) a compelling company to consider, especially given its striking revenue growth of 1,093.20%. Based in Mechelen,..

Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Unpacking a 35.24% Upside Potential

Edgewise Therapeutics, Inc. (EWTX), a burgeoning name in the biotechnology sector, is capturing the attention of investors with its promising 35.24% potential upside. The company’s focus on developing groundbreaking therapies..

Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Robust Growth Potential with 23% Upside

Investors eyeing opportunities in the healthcare sector may want to take a closer look at Kiniksa Pharmaceuticals International (NASDAQ: KNSA). With a market capitalization of $3.49 billion and a unique..

Ardent Health, Inc. (ARDT) Stock Analysis: A 37.83% Potential Upside in Focus for Investors

Ardent Health, Inc. (NYSE: ARDT) stands out in the healthcare sector as a robust player in the medical care facilities industry. With a market capitalization of $1.36 billion, this Brentwood,..

Organon & Co. (OGN) Stock Analysis: Key Insights on Its 25.17% Potential Upside

For investors with a keen interest in the healthcare sector, Organon & Co. (NYSE: OGN) offers a compelling case study. With a market capitalization of $1.87 billion, this U.S.-based company..

Crinetics Pharmaceuticals (CRNX) Stock Analysis: Unpacking a 105% Potential Upside for Growth Investors

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is capturing the attention of growth-oriented investors with its compelling development pipeline and an eye-catching potential upside of 105.26%. The company, headquartered in San Diego,..

ICU Medical, Inc. (ICUI) Investor Outlook: A 24% Upside Potential Amid Healthcare Innovation

ICU Medical, Inc. (NASDAQ: ICUI) presents a compelling opportunity for investors seeking exposure in the healthcare sector, particularly within the medical instruments and supplies industry. With a market capitalization of..

ImmunityBio, Inc. (IBRX) Stock Analysis: A Biotech Powerhouse with 29% Upside Potential

ImmunityBio, Inc. (NASDAQ: IBRX) stands as a formidable player in the biotechnology sector, capturing investor interest with its innovative approach to immunotherapy. With a market cap of $10.73 billion, this..

Search

Funds

March 3, 2026

Search

Funds

March 3, 2026

FTSE 100

Funds